|
End-of-day quote
New Zealand S.E.
02/10/2026
|
5-day change | 1st Jan Change | ||
| 4.370 NZD | +1.16% |
|
-0.46% | +29.29% |
| 09-08 | Aft Pharmaceuticals Limited Partners with Mark Cuban Cost Plus Drug Company to Bring Combogesic to the U.S | CI |
| 07-31 | AFT Pharmaceuticals Limited - Shareholder/Analyst Call |
| Market Cap | 458M 257M 228M 213M 194M 367M 24.72B 370M 2.58B 1B 12.64B 966M 945M 40.56B | P/E 2027 * |
23.3x | P/E 2028 * | 18.5x |
|---|---|---|---|---|---|
| Enterprise Value | 488M 274M 243M 227M 207M 390M 26.33B 394M 2.75B 1.07B 13.46B 1.03B 1.01B 43.2B | EV / Sales 2027 * |
1.61x | EV / Sales 2028 * | 1.4x |
| Free-Float |
22.37% | Yield 2027 * |
0.75% | Yield 2028 * | 0.95% |
| Markets | Quality | ||
|---|---|---|---|
New Zealand S.E.
| AFT | End-of-day quote | |
Australian S.E.
| AFP | Delayed |
Last Transcript: AFT Pharmaceuticals Limited
| 20/01/24 | Rentevrees zet Bel20 onder druk | |
| 19/01/24 | KBC uitblinker op groene beurs | |
| 19/01/24 | Brusselse beurs opent flink hoger | |
| 19/01/24 | Brussel start handelsdag vermoedelijk in het groen | |
| 18/01/24 | Hyloris gaat samenwerken met AFT Pharmaceuticals |
| 1 day | +1.16% | ||
| 1 week | -0.46% | ||
| Current month | +1.63% | ||
| 3 months | +18.11% | ||
| 6 months | +30.06% | ||
| Current year | +29.29% |
| 1 week | 4.26 |  | 4.4 |
| 1 month | 4.2 | | 4.48 |
| Current year | 3.35 | | 4.85 |
| 1 year | 2.79 | | 4.85 |
| 3 years | 2.37 | | 4.85 |
| 5 years | 2.37 | | 5 |
| 10 years | 1.7 | | 5.65 |
| Manager | Title | Age | Since |
|---|---|---|---|
Marree Atkinson
HRO | Human Resources Officer | - | 03/09/2012 |
Hartley Atkinson
CEO | Chief Executive Officer | - | 03/09/1997 |
Stuart Houliston
DFI | Director of Finance/CFO | - | 14/06/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
David Flacks
CHM | Chairman | - | 21/06/2015 |
Hartley Atkinson
BRD | Director/Board Member | - | 03/09/1997 |
Marree Atkinson
BRD | Director/Board Member | - | 03/09/2012 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 03/07/25 | Buy | Founder | 200,000 | 0.1907% | ||
| 26/06/25 | Free | Founder | 17,755 | 0.0169% | ||
| 02/12/24 | Buy | Founder | 45 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.16% | -0.46% | +56.63% | +31.23% | 257M | |
| -0.61% | -3.43% | +36.07% | +115.04% | 1,019B | |
| -1.02% | -5.60% | +35.72% | +64.63% | 617B | |
| +1.11% | -0.58% | +12.36% | +77.95% | 464B | |
| +0.34% | -3.01% | +61.79% | +41.24% | 356B | |
| -0.95% | -4.05% | +20.54% | +41.71% | 333B | |
| -1.46% | -2.89% | +10.57% | +32.81% | 267B | |
| -1.35% | -5.43% | -6.17% | +8.98% | 244B | |
| -1.04% | -2.79% | +35.30% | +51.84% | 218B | |
| -1.87% | -4.10% | +28.44% | +93.66% | 179B | |
| Average | -0.57% | -3.14% | +29.13% | +55.91% | 369.74B | |
| Weighted average by Cap. | -0.60% | -3.54% | +29.08% | +70.56% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 304M 170M 151M 141M 129M 243M 16.39B 245M 1.71B 663M 8.38B 640M 626M 26.89B | 345M 194M 172M 161M 146M 276M 18.62B 279M 1.94B 753M 9.52B 727M 712M 30.56B |
| Net income | 19.7M 11.05M 9.82M 9.16M 8.35M 15.75M 1.06B 15.9M 111M 42.98M 543M 41.49M 40.59M 1.74B | 24.81M 13.92M 12.37M 11.55M 10.52M 19.85M 1.34B 20.03M 140M 54.15M 684M 52.28M 51.14M 2.2B |
| Net Debt | 29.84M 16.74M 14.88M 13.88M 12.65M 23.87M 1.61B 24.09M 168M 65.11M 823M 62.86M 61.49M 2.64B | 24.6M 13.8M 12.26M 11.45M 10.43M 19.68M 1.33B 19.86M 139M 53.67M 678M 51.82M 50.7M 2.18B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/10/26 | NZ$4.370 | +1.16% | 9,913 |
| 01/10/26 | NZ$4.320 | +0.47% | 7,954 |
| 30/09/26 | NZ$4.300 | -0.92% | 23,427 |
| 29/09/26 | NZ$4.340 | -0.23% | 12,849 |
| 28/09/26 | NZ$4.350 | -0.91% | 23,403 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- AFT Stock
Select your edition
All financial news and data tailored to specific country editions
